May 27, 2025 07:05 AM EDTUpdated 01:57 PM

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

Elizabeth Cairns

Senior biopharma journalist

Prothena said last week it had abandoned its lead product after a Phase 3 amyloidosis failure and is planning “substantial” layoffs. The company previously …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Biogen taps City Therapeutics in RNAi deal worth up to $1B

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way